Drug-induced lupus erythematosus;Lupus indotto da farmaci

Reumatismo

Volumn 55, Issue 3, 2003, Pages 147-154

  Atzeni, Fabiola ^a   Marrazza, M G ^a   Sarzi Puttini, P ^a   Carrabba, M ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Anti histone antibodies; Autoantibodies; Autoimmunity; Drug induced lupus

Indexed keywords

ALPHA INTERFERON; AMIODARONE; ANTICONVULSIVE AGENT; ANTILIPEMIC AGENT; ANTINUCLEAR ANTIBODY; ANTITHYROID AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORPROMAZINE; CLOBAZAM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GOLD SALT; HYDRALAZINE; INFLIXIMAB; INTERLEUKIN 2; ISONIAZID; LAMOTRIGINE; METHYLDOPA; MINOCYCLINE; PENICILLAMINE; PENICILLIN DERIVATIVE; PROCAINAMIDE; QUINIDINE; SALAZOSULFAPYRIDINE; STREPTOMYCIN; SULFADIAZINE; TETRACYCLINE; THIAZIDE DIURETIC AGENT; TICLOPIDINE; UNINDEXED DRUG; VALPROIC ACID;

ARTHRALGIA; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DRUG INDUCED DISEASE; FEVER; HUMAN; LUPUS LIKE SYNDROME; MYALGIA; PLEURISY; RASH; REVIEW; RISK FACTOR; SYMPTOM; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIBODIES, ANTINUCLEAR; ANTIBODY SPECIFICITY; AUTOANTIBODIES; AUTOIMMUNE DISEASES; HISTONES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PHARMACEUTICAL PREPARATIONS;

EID: 0141558956     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Hess E. Drug-related lupus. N Engl J Med 1988; 318: 1460-2.
2. Yung UR, Richardson BC. Drug-induced lupus. Rheum Dis Clin of North Am 1994; 20: 61-86.
3. Burlingame RW, Rubin RL. Drug-induced anti-histone autoantibodies display two patterns of reactivity with substructures of chromatin. J Clin Invest 1991; 88: 680-90.
4. Totoritis MC, Tan EM, McNally EM, Rubin RL. Association of antibody to histone complex H2A-H2B with symptomatic procainamide-induced lupus. N Engl I Med 1988; 318: 1431-6.
5. Gioud M, Kaci MA, Monier JC. Histone antibodies in systemic lupus erythematosus. A possible diagnostic tool. Arthritis Rheum 1982; 25: 407-13.
6. Cohen WG, Webb J. Antihistone antibodies in rheumatoid arthritis and Felty's syndrome. Arthritis Rheum 1989; 32: 1319-24.
7. Malleson P, Petty RE, Fung M, Candido EP. Reactivity of antinuclear antibodies with histones and other antigens in juvenile rheumatoid arthritis. Arthritis Rheum 1989; 32: 919-23.
8. Molden DP, Klippe GL, Peebles CL, Rubin RL, Nakamura RM, Tan EM. IgM-anti-histone H-3 antibody associated with undifferentiated rheumatic disease syndromes. Arthritis Rheum 1986; 29: 39-46.
9. Portanova JP, Arndt RE, Tan EM, Kotzin BL. Anti-histone antibodies in idiopathic and drug-induced lupus recognize distinct intrahistone regions. J Immunol 1987; 138: 446-51.
10. Rubin RL, McNally EM, Nusinow SR, Robinson CA, Tan EM. IgG antibodies to the histone complex H2A-H2B characterize procainamide-induced lupus. Clin Immunol Immunopathol 1985; 36: 49-59.
11. Bray VJ, West SG, Schultz KT, Boumpas DT, Rubin RL. Anti-histone antibody profile in sulfasalazine-induced lupus. J Rheumatol 1994; 21: 2157-8.
12. Enzenauer RJ, West SG, Rubin RL. D-penicillamine-induced lupus erythematosus. Arthritis Rheum 1990; 33: 1582-5.
13. Hofstra A. Metabolism of hydralazine: Relevance to drug-induced lupus. Drug Metab Rev 1994; 26: 1357-8.
14. Hildreth EA, Biro CE, McCreary TA. Persistence of the "hydralazine syndrome": A follow-up study of eleven case. JAMA 1960; 173: 657-60.
15. Batchelor JR, Welsh KI, Tinoco RM, Dollery CT, Hughes GR, Bernstein R. Hydralazine-induced systemic lupus erythematosus: Influence of HLA-DR and sex on susceptibility. Lancet 1980; 24: 1107-9.
16. Torffvit O, Thysell H, Nassberger L. Occurrence of autoantibodies directed against myeloperoxidase and elastase in patients treated with hydralazine and presenting with glomerulonephritis. Hum Exp Toxicol 1994; 13: 563-7.
17. Nassberger L, Hultquist Ú, Sturfelt G. Occurrence of anti-lactoferrin antibodies in patients with systemic lupus erythematosus, hydralazine-induced lupus, and rheumatoid arthritis. Scand J Rheumatol 1994; 23: 206-10.
18. Peterson LL. Hydralazine-induced systemic lupus erythematosus presenting as pyoderma gangrenosum-like ulcers. J Am Acad Dermatol 1984; 10: 379-84.
19. Ladd AT. Procainamide-induced lupus erythematosus. N Engl J Med 1962; 267: 1357-8.
20. Lee SL, Chase PH. Drug-induced systemic lupus erythematosus: a critical review. Semin Arthritis Rheum 1975; 5: 83-103.
21. Uretrech JP. Mechanism of drug-induced lupus. Chem Res Toxicol 1988; 1: 134-43.
22. Rubin RL, Burlingame RW, Arnott JE, Totoritis MC, McNally EM, Johnson D. IgG but not other classes of anti-(H2A-H2B)-DNA is an early sign of procainamide-induced lupus. J Immunol 1995; 154: 2483-93.
23. Dubois EL. Procainamide induction of a systemic lupus erythematosus-like syndrome. Medicine 1969; 48: 217-28.
24. Muramatsu M, Nakajiama M, Mori M, Sobashima H, Sand H, Katao K. A case of primary antiphospholipid antibody syndrome associated with procainamide-induced systemic lupus erythematosus. Nippon Naika Gakkai Zasshi 1995; 84: 1736-8.
25. Blomgren SE, Vaughan GH. The immunogenecity of photo-oxidized DNA and of the product of DNA and procainamide-induced lupus. Arthritis Rheum 1968; 11: 470.
26. Rothfield NF, Bierer WF, Oberg, KE. Isoniazid induction of antinuclear antibodies. A prospective study. Ann Inter Med 1978; 88: 650-52.
27. Perry HMJr, Tan EM, Carmody S, Sakamoto A. Relationship of acetyl transferase activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine. J Lab Clin Med 1970; 76: 1124-25.
28. Sherman JD, Love DE, Harrington JF. Anemia, positive lupus and rheumatoid factors with methyldopa. Arch Intern Med 1967; 120: 321-6.
29. Sakurai Y, Kurihara R, Takeuchi M, Suga S, Owada K, Yoneshima H. A case of SLE-like syndrome and severe haemolytic anaemia caused by methyldopa. Nippon Naika Gakkai Zasshi 1995; 84: 2069-71.
30. Alarcon-Segovia D, Fishbein E, Cetina JA, Raya RJ, Barrera E. Antigenic specificity of clorpromazine-induced antinuclear antibodies. Clin Exp Immunol 1973; 15: 543-8.
31. Canoso RT, De Oliveira RM. Clorpromazine-induced anticardioplipin antibodies and lupus anticoagulant: Absence of thrombosis. Am J Hematol 1988; 27: 272-5.
32. Alloway JA, Salata MP. Quinidine-induced rheumatic syndromes. Semin Arthritis Rheum 1995; 24: 315-22.
33. Khattak FH, Morris IM, Mattingly PC. Sulphasalazine-induced systemic lupus erythematosus in a patient with rheumatoid arthritis. Br J Rheumatol 1996; 35: 104.
34. Bray VJ, West SG, Schultz KT, Boumpas DT, Rubin RL. Antihistone antibody profile in sulfasalazine-induced lupus. J Rheumatol 1994; 21: 2157-8.
35. Mielke H, Wildhagen K, Mau W, Ziedler H. Follow-up of patients with double-stranded DNA antibodies induced by sulfasalazine during the treatment of inflammatory rheumatic diseases. Sand J Rheumatol 1993; 22: 229-301.
36. Dvory VE, Just I, Korezym AD. Carbamezepin-induced systemic lupus erythematosus. Clin Neuropharmacol 1989; 12: 115-8.
37. Ansell BM. Drug-induced systemic lupus erythematosus in a nine-year old boy. Lupus 1992; 2: 193-4.
38. Sato-Matsumura KC, Koizumi H, Mazumura T, Takahashi T, Adachi K, Ohkawara A. Lupus erythematosus-like syndrome induced by thimazole and propylthiouracil. J Dermatol 1994; 21: 501-7.
39. Kawachi Y, Nukaga H, Hoshino N, Iwata M, Otsuka F. ANCA-associated vasculitis and lupus-like syndrome caused by methymazole. Clin Exp Dermatol 1995; 20: 345-7.
40. Tsankov N, Lazarova A, Vasileva S, Obreshkova EV. Lupus erythematosus-like syndrome eruption due to D-penicillamine in progressive systemic sclerosis. Int J Dermatol 1990; 29: 571-4.
41. Walshe J. Penicillamine and the SLE syndrome. J Rheumatol 1981; 8 (Suppl): 155-60.
42. Goodrich A, Kohn S. Hydrochlorthiazide-induced lupus erythematosus: A new variant? J Am Acad Dermatol 1993; 28: 1001-2.
43. Darken M, McBurney E. Subacute cutaneous-like drug eruption due combination diuretic hydrochlorthiazide and triamterene. J Am Acad Dermatol 1988; 18: 38-42.
44. Zamber RW, Starkebaum G, Rubin RL, Martens HF, Wener MH. Drug-induced systemic lupus erythematosus due to ophthalmic timolol. J Rheumatol 1992; 19: 977-9.
45. Eady EA, Jones CE, Tipper JL, Cove JH, Cunliffe WJ, Layton AM. Antibiotic resistant propionibacteria in acne: Need for policies to modify in antibiotic usage. Br Med J 1996; 312: 169-72.
46. Gordon MM, Porter D. Minocycline induced lupus: case series in the West of Scotland. J Rheumatol 2001; 28: 1004-6.
47. Knitzer RH, White Needlemann B. Musculoskeletal syndromes associated with acne. Semin Arthritis Rheum 1991; 20: 247-55.
48. Schlienger RG, Bircher AJ, Meier CR. Minocycline-induced lupus. Dermatology 2000; 200: 223-31
49. Bleck TP, Smith MC. Possible induction of systemic lupus erythematosus by valproate. Epilepsia 1994; 35: 162-3.
50. Akard L, Hoffman R, Elias L, Saiers JH. Alpha-interferon and immune hemolytic anemia. Ann Inter Med 1986;105:306.
51. McLaughlin P, Talpaz M, Quesada JR, Saleem A, Barlogie B, Gutterman JU. Immune Thrombocytopenia following α-interferon therapy in patients with cancer. J Am Med Assoc 1985; 254: 1353-4.
52. Burman P, Totterman TH, Oberg K, Karlsson FA. Thyroid autoimmunity in patients on long-term therapy with leukocyte-derived interferon. J Clin Endrocrinol Metab 1986; 63: 1086-90.
53. Wandl UB, Nagel-Hiemke M, May D, Kreuzfelder E, Kloke O, Kranzhoff M, et al. Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders. Clin Immunol Immunopathol 1992; 65: 70-4.
54. Gonzalo JA, Cuende E, Ales-Martinez JE, Martinez-AC, Kroemer G. Interleukin-2: a possible trigger of autoimmunity. Int Arch Allergy Immunol 1992; 97: 251-7.
55. Massarotti LM, Lui NY, Mier J, Atkins MB. Chronic inflammatory arthritis after treatment with high-dose interleukin-2 for malignancy. Am J Med 1992; 92: 693-7.
56. Fritzler MJ. Drugs recentely associated with lupus syndromes. Lupus 1994; 3: 455-9.
57. Caramaschi P, Biasi D, Carletto A, Manzo T, Barbara LM. Clobazam-induced systemic lupus erythematosus. Clin Rheumatol 1995; 14: 116.
58. Sarzi-Puttini P, Panni B, Cazzola M, Muzzupappa S, Turiel M. Lamotrigine-induced lupus. Lupus 2000; 9: 555-7.
59. Favalli EG, Sinigaglia L, Varenna M, Arnoldi C. Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. Lupus 2002; 11: 753-5.
60. Sarzi-Puttini P, Ardizzone S, Manzionna G, Atzeni F, Colombo E, Antivalle M, et al. Infliximab-induced lupus in Crohn's disease: a case report. Submitted for publication.
61. Bertin P, Kamdem J, Bonnet C, Arnaud M, Treves R. Captopril induced lupus. Clin Exp Rheumatol 1993; 11: 695.
62. Schwartz D, Pines A, Averbuch M, Levo Y. Enalapril-induced antinuclear antibodies. Lancet 1990; 336: 187.
63. Carter JD, Valeriano-Marcet J, Kanik KS, Vasey FB. Antinuclear antibody-negative, drug-induced lupus caused by lisinopril. South Med J 2001; 94: 1122-3.
64. Spiera RF, Bermnan RS, Werner AJ, Spiera H. Ticlopidine-induced lupus: a report of 4 cases. Arch Intern Med 2002; 162: 2240-3.
65. Sheikhadeh A, Schafer U, Schnabel A. Drug-induced lupus erythematosus by amiodarone. Arch Inter Med 2002; 162: 834-6.
66. Goldman JA, Fishman AB, Lee JE, Johnson RJ. The role of cholesterol lowering agents in drug-induced rhabdomyolysis and polymyositis. Arthritis Rheum 1989; 32: 358-9.
67. Ahmad S. Lovastatin-induced lupus erythematosus. Ann Inter Med 1991; 151: 1667-8.
68. Bannwaarth B, Miremont G, Papapietro PM: Lupus-like syndrome associated with simvastatin. Arch Intern Med 1992; 152: 1093.
69. Pramatarov KR. Drug-induced lupus erythematosus. Clin Dermatol 1998; 16: 367-77.
70. di Fazano CS, Bertin P. The pharmacological management of drug-induced rheumatic disorders. Expert Opin Pharmacother 2001; 10: 1623-31.